Literature DB >> 20087127

Hospital costs associated with shunt infections in patients receiving antibiotic-impregnated shunt catheters versus standard shunt catheters.

Frank J Attenello1, Giannina L Garces-Ambrossi, Hasan A Zaidi, Daniel M Sciubba, George I Jallo.   

Abstract

BACKGROUND: The average hospital cost for shunt infection treatment is $50,000, making it the most financially costly implant-related infection in the United States. We set out to determine whether introduction of antibiotic-impregnated shunts (AISs) in our practice has decreased the incidence of shunt infection or decreased infection-related hospital costs at our institution.
METHODS: Clinical and hospital billing records of pediatric patients undergoing cerebrospinal fluid (CSF) shunt insertion at a single institution from April 2001 to December 2006 were retrospectively reviewed. Eighteen months before October 2002, all CSF shunts included standard, non-AIS catheters. During the 4 years after October 2002, all CSF shunts included AIS catheters. Patients were followed at least 18 months after surgery.
RESULTS: A total of 406 pediatric patients underwent 608 shunt placement procedures (400 AISs, 208 non-AISs). Of patients with non-AIS catheters, 25 (12%) experienced shunt infection, whereas only 13 patients (3.2%) with AIS catheters experienced shunt infection during follow-up (P < .001). The total hospital cost to treat 25 non-AIS shunt infections over the first 18 months was $1,234,928. The total hospital cost to treat 13 AIS shunt infections over the past 4 years was $606,328. The mean hospital cost per shunt infection was similar for infected AIS and non-AIS catheters ($46,640 vs. $49,397). However, the infection-related hospital cost per 100 patients shunted was markedly lower in the AIS cohort than in the non-AIS cohort ($151,582 vs. $593,715). DISCUSSION: The introduction of AIS catheters in our institutional practice reduced the incidence of shunt infection and resulted in significant hospital cost savings. AIS systems are efficient and cost-effective instruments to prevent perioperative colonization of CSF shunt components.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20087127     DOI: 10.1227/01.NEU.0000363405.12584.4D

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  14 in total

Review 1.  Evidence-based interventions to reduce shunt infections: a systematic review.

Authors:  Nehaw Sarmey; Varun R Kshettry; Michael F Shriver; Ghaith Habboub; Andre G Machado; Robert J Weil
Journal:  Childs Nerv Syst       Date:  2015-02-17       Impact factor: 1.475

2.  Risk factors for surgical site infection following nonshunt pediatric neurosurgery: a review of 9296 procedures from a national database and comparison with a single-center experience.

Authors:  Brandon Sherrod; Anastasia Arynchyna; James Johnston; Curtis Rozzelle; Jeffrey Blount; W. Jerry Oakes; Brandon Rocque
Journal:  J Neurosurg Pediatr       Date:  2017-02-10       Impact factor: 2.375

Review 3.  Central Nervous System Device Infections.

Authors:  Rodrigo Hasbun
Journal:  Curr Infect Dis Rep       Date:  2016-11       Impact factor: 3.725

4.  Route of antibiotic prophylaxis for prevention of cerebrospinal fluid-shunt infection.

Authors:  Sebastian Hhmj Arts; Hieronymus Damianus Boogaarts; Erik J van Lindert
Journal:  Cochrane Database Syst Rev       Date:  2019-06-04

5.  2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis.

Authors:  Allan R Tunkel; Rodrigo Hasbun; Adarsh Bhimraj; Karin Byers; Sheldon L Kaplan; W Michael Scheld; Diederik van de Beek; Thomas P Bleck; Hugh J L Garton; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

6.  Transverse sinus stenting for pseudotumor cerebri: a cost comparison with CSF shunting.

Authors:  R M Ahmed; F Zmudzki; G D Parker; B K Owler; G M Halmagyi
Journal:  AJNR Am J Neuroradiol       Date:  2013-11-28       Impact factor: 3.825

7.  Evaluation of an in vivo model for ventricular shunt infection: a pilot study using a novel antimicrobial-loaded polymer.

Authors:  Rajiv R Iyer; Noah Gorelick; Karen Carroll; Ari M Blitz; Sarah Beck; Caroline M Garrett; Audrey Monroe; Betty Tyler; Sean T Zuckerman; Jeffrey R Capadona; Horst A von Recum; Mark G Luciano
Journal:  J Neurosurg       Date:  2018-08-03       Impact factor: 5.115

8.  Protective effect of rifampicin and clindamycin impregnated devices against Staphylococcus spp. infection after cerebrospinal fluid diversion procedures.

Authors:  Raquel Gutiérrez-González; Gregorio R Boto; Cristina Fernández-Pérez; Náyade del Prado
Journal:  BMC Neurol       Date:  2010-10-12       Impact factor: 2.474

9.  The British antibiotic and silver-impregnated catheters for ventriculoperitoneal shunts multi-centre randomised controlled trial (the BASICS trial): study protocol.

Authors:  Michael D Jenkinson; Carrol Gamble; John C Hartley; Helen Hickey; Dyfrig Hughes; Michaela Blundell; Michael J Griffiths; Tom Solomon; Conor L Mallucci
Journal:  Trials       Date:  2014-01-03       Impact factor: 2.279

10.  Silver-impregnated, antibiotic-impregnated or non-impregnated ventriculoperitoneal shunts to prevent shunt infection: the BASICS three-arm RCT.

Authors:  Conor L Mallucci; Michael D Jenkinson; Elizabeth J Conroy; John C Hartley; Michaela Brown; Tracy Moitt; Joanne Dalton; Tom Kearns; Michael J Griffiths; Giovanna Culeddu; Tom Solomon; Dyfrig Hughes; Carrol Gamble
Journal:  Health Technol Assess       Date:  2020-03       Impact factor: 4.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.